Inheritor Cell Technology

ictcells.com

Inheritor_Cell_Technology
As a forthcoming biomedical clinic, Inheritor Cell Technology, Inc. accentuates its focus on stem cell research and clinical applications. We are committed to the development of stem cell preparation, application treatment and pharmaceuticals, with an emphasis on human health services such as disease research, genetic testing, assisted reproduction, organ regeneration, genetic science, and many more through human-derived biological sample banks. Dr. An is our Chief Medical Officer of ICT U.S. who is also the world’s most renewed stem cell therapist with tens of thousands of clinical treatment cases followed by twenty-six National Institutes of Health (NIH) and Food and Drug Administration (FDA) clinical trial registrations, both of which have successfully passed Phase III clinical trials. During this rapid growth of Artificial Intelligence (AI), we are profoundly aware that our future will not only lead to the development of smarter machines, but also making humans healthier.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

BONE THERAPEUTICS AND LINK HEALTH SIGN A NON-BINDING TERM SHEET FOR THE GLOBAL RIGHTS OF ALLOB

Bone Therapeutics | November 29, 2021

news image

BONE THERAPEUTICS the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Link Health Pharma Co., Ltd announce the signing of a non-binding term sheet for the global rights for ALLOB, Bone Therapeutics’ allogeneic bone cell therapy. Subject to the fulfillment of customary condition precedents, Bone Therapeutics and Link Health aim to complete the final agreement and to fully execute it by the end of 2021. This new partnership is s...

Read More

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

news image

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More

MedTech, Industrial Impact

CONCERTAI RELEASES CTO 2.0, A NEXT GENERATION AI SAAS SOLUTION FOR ONCOLOGY CLINICAL TRIAL DESIGN AND OPTIMIZATION

Prnewswire | April 06, 2023

news image

ConcertAI, LLC a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence solutions for life sciences and healthcare, announced the release of its next generation of Clinical Trial Optimization (CTO 2.0). "Trial sponsors have a range of new imperatives they're trying to meet: assuring that the trial population is reflective of the ultimate population that would have access to the drug; to set and meet diversity goals for those ethnic, racial and econ...

Read More

MedTech

PRECISION COATING ANNOUNCES MERGER WITH N2 BIOMEDICAL TO EXPAND MEDICAL COATINGS PLATFORM

N2 Biomedical | September 20, 2021

news image

Precision Coating, a leading medical coatings service provider to interventional, orthopedic, and advanced surgical markets, is pleased to announce a merger with N2 Biomedical, a Bedford, MA-based company. N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies. ...

Read More
news image

Cell and Gene Therapy

BONE THERAPEUTICS AND LINK HEALTH SIGN A NON-BINDING TERM SHEET FOR THE GLOBAL RIGHTS OF ALLOB

Bone Therapeutics | November 29, 2021

BONE THERAPEUTICS the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Link Health Pharma Co., Ltd announce the signing of a non-binding term sheet for the global rights for ALLOB, Bone Therapeutics’ allogeneic bone cell therapy. Subject to the fulfillment of customary condition precedents, Bone Therapeutics and Link Health aim to complete the final agreement and to fully execute it by the end of 2021. This new partnership is s...

Read More
news image

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More
news image

MedTech, Industrial Impact

CONCERTAI RELEASES CTO 2.0, A NEXT GENERATION AI SAAS SOLUTION FOR ONCOLOGY CLINICAL TRIAL DESIGN AND OPTIMIZATION

Prnewswire | April 06, 2023

ConcertAI, LLC a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence solutions for life sciences and healthcare, announced the release of its next generation of Clinical Trial Optimization (CTO 2.0). "Trial sponsors have a range of new imperatives they're trying to meet: assuring that the trial population is reflective of the ultimate population that would have access to the drug; to set and meet diversity goals for those ethnic, racial and econ...

Read More
news image

MedTech

PRECISION COATING ANNOUNCES MERGER WITH N2 BIOMEDICAL TO EXPAND MEDICAL COATINGS PLATFORM

N2 Biomedical | September 20, 2021

Precision Coating, a leading medical coatings service provider to interventional, orthopedic, and advanced surgical markets, is pleased to announce a merger with N2 Biomedical, a Bedford, MA-based company. N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies. ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us